Healthcare
Live Price
Offline$26.78
+2.06% today
1Y Change
+18.17%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Koninklijke Philips N.V. (PHG) is a Healthcare stock with a market cap of $21.30B and listed on NYSE. The stock last traded around $26.78 and up 18.2% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of -1.0%, EPS growth of +226.7%, a dividend yield of 3.8%. What stands out right now is revenue -1.0%, EPS +226.7%, free cash flow -34.1% with operating margin 8.6% and ROIC 5.7%. The dividend matters to the case here, with a current yield around 3.8%. Valuation is more restrained than many high-expectation growth names at P/E 23.8 and price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PHG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHG Max Drawdown
-23.34%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$17.2B
-3.8% YoY
FY Net Income
$3.3B
+306.4% YoY
Free Cash Flow
$1.5B
+324.7% YoY
Revenue Growth
-1.0%
EPS Growth
+226.7%
Gross Margin
45.2%
Net Margin
5.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 17.8B | 18.0B | 18.2B | 17.8B | 17.2B |
| Gross Profit | 8.1B | 7.8B | 7.4B | 7.2B | 7.2B |
| Operating Income | 1.4B | 529M | -115M | -1.5B | 553M |
| EBITDA | 2.6B | 1.8B | 1.0B | 115M | 2.0B |
| Net Income | 895M | -702M | -466M | -1.6B | 3.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.8B | 2.4B | 1.9B | 1.2B | 2.3B |
| Total Assets | 26.9B | 29.0B | 29.4B | 30.7B | 31.0B |
| Total Liabilities | 16.0B | 16.9B | 17.3B | 17.4B | 16.5B |
| Shareholder Equity | 11.0B | 12.0B | 12.0B | 13.2B | 14.4B |
| Total Debt | 8.1B | 7.5B | 7.3B | 7.3B | 6.0B |
| Net Debt | 5.3B | 5.1B | 5.4B | 6.2B | 3.7B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.9B
+1159.6% YoY
Capital Expenditures
469M
-0.6% YoY
Free Cash Flow
1.5B
+324.7% YoY
Key ratios
Gross Margin
45.2%
Operating Margin
8.6%
Net Margin
5.0%
ROE
8.2%
Debt / Equity
0.74x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.